- Home
- KPTI vs BGSF Comparison
KPTI vs BGSF Comparison
Compare KPTI & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- BGSF
- Stock Information
- Founded
- KPTI 2008
- BGSF 2007
- Country
- KPTI United States
- BGSF United States
- Employees
- KPTI N/A
- BGSF N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- BGSF Professional Services
- Sector
- KPTI Health Care
- BGSF Consumer Discretionary
- Exchange
- KPTI Nasdaq
- BGSF Nasdaq
- Market Cap
- KPTI 51.7M
- BGSF 54.8M
- IPO Year
- KPTI 2013
- BGSF N/A
- Fundamental
- Price
- KPTI $7.36
- BGSF $3.33
- Analyst Decision
- KPTI Strong Buy
- BGSF Strong Buy
- Analyst Count
- KPTI 5
- BGSF 1
- Target Price
- KPTI $61.00
- BGSF $9.00
- AVG Volume (30 Days)
- KPTI 101.5K
- BGSF 18.9K
- Earning Date
- KPTI 05-12-2025
- BGSF 05-07-2025
- Dividend Yield
- KPTI N/A
- BGSF N/A
- EPS Growth
- KPTI N/A
- BGSF N/A
- EPS
- KPTI N/A
- BGSF N/A
- Revenue
- KPTI $145,237,000.00
- BGSF $272,499,000.00
- Revenue This Year
- KPTI $4.87
- BGSF $4.90
- Revenue Next Year
- KPTI $16.29
- BGSF N/A
- P/E Ratio
- KPTI N/A
- BGSF N/A
- Revenue Growth
- KPTI N/A
- BGSF N/A
- 52 Week Low
- KPTI $3.51
- BGSF $2.91
- 52 Week High
- KPTI $18.00
- BGSF $9.26
- Technical
- Relative Strength Index (RSI)
- KPTI 68.69
- BGSF 47.32
- Support Level
- KPTI $5.52
- BGSF $3.15
- Resistance Level
- KPTI $6.56
- BGSF $3.47
- Average True Range (ATR)
- KPTI 0.56
- BGSF 0.20
- MACD
- KPTI 0.34
- BGSF 0.05
- Stochastic Oscillator
- KPTI 86.12
- BGSF 64.62
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About BGSF BGSF Inc.
BGSF Inc is a provider of workforce solutions operating primarily in the U.S. across two segments: Property Management and Professional. In the Property Management segment, BGSF offers office and maintenance talent to clients, facilitating their staffing needs with short-term and consulting solutions. The Professional segment specializes in IT, offering skilled professionals in SAP, Workday, and other areas to Fortune 500 companies and consulting firms nationwide. BGSF's workforce services include on-demand assignments, consulting, and managed solutions, allowing clients to flexibly manage their workforce needs. With a focus on converting fixed personnel costs to variable expenses, BGSF enables companies to effectively address fluctuations in demand while optimizing costs.